TY - JOUR
T1 - New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam
AU - Zarogoulidis, Paul
AU - Kioumis, Ioannis
AU - Ritzoulis, Christos
AU - Petridis, Dimitris
AU - Darwiche, Kaid
AU - Porpodis, Konstantinos
AU - Spyratos, Dionysis
AU - Parrish, Scott
AU - Browning, Robert
AU - Li, Qiang
AU - Turner, J. Francis
AU - Freitag, Lutz
AU - Zarogoulidis, Konstantinos
PY - 2013
Y1 - 2013
N2 - Background: Several aerosol antibiotics are on the market and several others are currently being evaluated. Aim of the study was to evaluate the aerosol droplet size of five different antibiotics for future evaluation as an aerosol administration. Materials and methods: The nebulizers Sunmist®, Maxineb® and Invacare® were used in combination with four different "small <6 ml" residual cups and two "large <10 ml" with different loadings 2-4-6-8 ml (8 ml only for large residual cups) with five different antibiotic drugs (ampicilln-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam). The Mastersizer 2000 (Malvern) was used to evaluate the produced droplet size from each combination Results: Significant effect on the droplet size produced the different antibiotic (F = 96.657, p < 0.001) and the residual cup design (F = 68.535, p < 0.001) but not the different loading amount (p = 0.127) and the nebulizer (p = 0.715). Interactions effects were found significant only between antibiotic and residual cup (F = 16.736, p < 0.001). No second order interactions were found statistically significant. Conclusion: Our results firstly indicate us indirectly that the chemical formulation of the drug is the main factor affecting the produced droplet size and secondly but closely the residual cup design.
AB - Background: Several aerosol antibiotics are on the market and several others are currently being evaluated. Aim of the study was to evaluate the aerosol droplet size of five different antibiotics for future evaluation as an aerosol administration. Materials and methods: The nebulizers Sunmist®, Maxineb® and Invacare® were used in combination with four different "small <6 ml" residual cups and two "large <10 ml" with different loadings 2-4-6-8 ml (8 ml only for large residual cups) with five different antibiotic drugs (ampicilln-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam). The Mastersizer 2000 (Malvern) was used to evaluate the produced droplet size from each combination Results: Significant effect on the droplet size produced the different antibiotic (F = 96.657, p < 0.001) and the residual cup design (F = 68.535, p < 0.001) but not the different loading amount (p = 0.127) and the nebulizer (p = 0.715). Interactions effects were found significant only between antibiotic and residual cup (F = 16.736, p < 0.001). No second order interactions were found statistically significant. Conclusion: Our results firstly indicate us indirectly that the chemical formulation of the drug is the main factor affecting the produced droplet size and secondly but closely the residual cup design.
KW - Aerosol
KW - Antibiotics
KW - Infection
UR - http://www.scopus.com/inward/record.url?scp=84883865137&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2013.07.040
DO - 10.1016/j.ijpharm.2013.07.040
M3 - Article
C2 - 23891745
AN - SCOPUS:84883865137
SN - 0378-5173
VL - 455
SP - 182
EP - 188
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1-2
ER -